An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
Latest Information Update: 12 May 2020
At a glance
- Drugs Budigalimab (Primary) ; SC 004 AbbVie (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Sponsors AbbVie
- 28 Apr 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - I
- 25 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.